From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
January 8, 2020
Philadelphia, PA, January 8, 2019 – IntegriChain, a leading life sciences commercial data and analytics company that helps drive patient access, today announced that the company has supported more than 65 launches of innovative therapies including cell and gene therapy (CGT) and orphan & rare diseases (ORD) during the last three years. Emerging Life Sciences manufacturers have engaged IntegriChain for its best-in-class comprehensive commercialization platform, including channel and patient data stewardship and managed services to stand up their business infrastructure for all aspects of patient access: contracts and pricing, gross-to-net, channel, and patient services.
“As we have expanded our ICyte platform for market access and commercialization, we are now the leading launch readiness partner for data aggregation and outsourcing services to Life Sciences manufacturers, from early-stage specialty and cell and gene innovators to mid-market and Big Pharma,” said IntegriChain Co-Founder and CEO Kevin Leininger. “With our benchmark data across more than 180 manufacturers, the depth of our commercialization insights is unsurpassed. We are the only platform that can provide the unique combination of aggregated and refined channel data, patient access visibility, expertise in contracting and pricing, and gross-to-net efficiency—all in a proven rapid-release launch blueprint that saves time and minimizes organizational disruption.”
About IntegriChain’s Launch Readiness and Commercialization Solutions IntegriChain delivers a full breadth of data products, SaaS applications, managed services, and professional services targeting launch readiness and commercialization:
Channel, including distribution and channel planning; market and channel analogs; channel awareness and stocking; sales and inventory uptake; daily business management; and Distributor QBRs.
Contracts and Pricing, including contract strategy and price guidelines; government price policies and SOPs; government and commercial contracts; filing of provisional, baseline, and initial government prices; rebate and chargeback processing; and payer contract QBRs.
Gross-to-Net, including GTN organization and process design; GTN methodology and implementation; forecast, liability, and accrual modeling; monthly accruals processing and close; training and knowledge transfer; and new contract strategy modeling.
Patient Access, including patient access model design and network design; data contract requirements documentation; specialty pharmacy agreement execution; patient status data aggregation and cleansing; problematic patient cases triaging; and specialty pharmacy QBRs.
About IntegriChain IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient access. Our mission is to help all stakeholders in pharmaceutical market access and commercialization improve patient initiation and adherence for life-saving and life-enhancing medicines. Our data-science-driven ICyte Platform and solutions uniquely focus on overcoming access challenges after the patient and provider commit to therapy. More than 180 life science manufacturers rely on insights delivered from IntegriChain’s aggregated and refined data, SaaS applications, managed services, and professional services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
